FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.
Similar Posts
Krasniy Oktyabr Inc. USA Issues Alert on Eviscerate Dry Salted Vobla “Aral Silver”
KRASNIY OKTYABR INC. USA. of BROOKLYN, NY, is recalling its “ARAL SILVER VOBLA” brand “ARAL”, because the product was found to be uneviscerated.Nephron Sc Inc. West Columbia, SC. 483 issued 08/22/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/22/2025
Short Title (70 char) Nephron Sc Inc. West Columbia, SC. 483 issued 08/22/2025
FEI Number 3010892830
Firm Name Nephron Sc Inc
Record Type 483
State SC
Establishment Type Sterile Drug ManufacturingGDUFA IV: Fiscal Years 2028 – 2032
Information related to FDA’s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.Liebel-Flarsheim Company LLC – 711508 – 10/17/2025
CGMP/Finished Pharmaceuticals/AdulteratedMyelodysplastic Syndromes: Developing Drug and Biological Products for Treatment
Myelodysplastic Syndromes: Developing Drug and Biological Products for TreatmentBiosimilar Product Information
This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.